Protein salvador homolog 1 acts as a tumor suppressor and is modulated by hypermethylation in pancreatic ductal adenocarcinoma

被引:17
作者
Wang, Lei [1 ]
Wang, Mei [2 ]
Hu, Chenxi [2 ]
Li, Pengping [3 ]
Qiao, Yun [1 ]
Xia, Youyou [1 ]
Liu, Liang [1 ]
Jiang, Xiaodong [4 ]
机构
[1] Lianyungang First Peoples Hosp, Dept Radiat Oncol, Lianyungang, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Affiliated Lianyungang Hosp, Dept Radiat Oncol, Tumor Lab, Xuzhou, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Sch Basic Med Sci, Dept Bioinformat, Nanjing, Jiangsu, Peoples R China
[4] Xuzhou Med Univ, Affiliated Lianyungang Hosp, Dept Radiat Oncol, Xuzhou, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
SAV1; tumor suppressor; pancreatic ductal adenocarcinoma; hypermethylation; PATHWAY TRANSCRIPTIONAL COACTIVATOR; HIPPO PATHWAY; CELL-PROLIFERATION; FOXM1; PROMOTES; CANCER; YAP; EXPRESSION; SIZE;
D O I
10.18632/oncotarget.17972
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Salvador (SAV) is a gene product that contains two protein-protein interaction modules known as WW domains and is believed to act as a scaffolding protein for Hippo and Warts. SAV1 is the human homolog of Salvador, which is the most well characterized upstream signaling component of Hippo pathway. Although its role in some tumors is known, SAV1 function in other types of tumors, including pancreatic tumor, is still obscure. Here, we determined the role of SAV1 in pancreatic ductal adenocarcinoma (PDAC) development and progression. Our results revealed that SAV1 suppressed expression promoted PDAC invasion and migration, and repressed pancreatic cancer cells apoptosis. Moreover, SAV1 was silenced by hypermethylation. Thus, SAV1 worked as a cancer suppressor and it might be considered as a target for pancreatic cancer therapy.
引用
收藏
页码:62953 / 62961
页数:9
相关论文
共 23 条
  • [1] [Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
  • [2] The Hippo Pathway in Biological Control and Cancer Development
    Chan, Siew Wee
    Lim, Chun Jye
    Chen, Liming
    Chong, Yaan Fun
    Huang, Caixia
    Song, Haiwei
    Hong, Wanjin
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2011, 226 (04) : 928 - 939
  • [3] Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway
    Chen, Meiyuan
    Wang, Min
    Xu, Simiao
    Guo, Xingjun
    Jiang, Jianxin
    [J]. ONCOTARGET, 2015, 6 (42) : 44466 - 44479
  • [4] FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression
    Cui, Jiujie
    Shi, Min
    Xie, Dacheng
    Wei, Daoyan
    Jia, Zhiliang
    Zheng, Shaojiang
    Gao, Yong
    Huang, Suyun
    Xie, Keping
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (10) : 2595 - 2606
  • [5] The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network
    Harvey, Kieran
    Tapon, Nicolas
    [J]. NATURE REVIEWS CANCER, 2007, 7 (03) : 182 - 191
  • [6] Pancreatic Cancer
    Hidalgo, Manuel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (17) : 1605 - 1617
  • [7] Khoo CP, 2011, TISSUE ENG PART C-ME, V17, P895, DOI [10.1089/ten.tec.2011.0150, 10.1089/ten.TEC.2011.0150]
  • [8] Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung
    Lange, Alexander W.
    Sridharan, Anusha
    Xu, Yan
    Stripp, Barry R.
    Perl, Anne-Karina
    Whitsett, Jeffrey A.
    [J]. JOURNAL OF MOLECULAR CELL BIOLOGY, 2015, 7 (01) : 35 - 47
  • [9] The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis
    Lee, Kwang-Pyo
    Lee, Joo-Hyeon
    Kim, Tae-Shin
    Kim, Tack-Hoon
    Park, Hee-Dong
    Byun, Jin-Seok
    Kim, Min-Chul
    Jeong, Won-Il
    Calvisi, Diego F.
    Kim, Jin-Man
    Lim, Dae-Sik
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (18) : 8248 - 8253
  • [10] Regulators of mammalian Hippo pathway in cancer
    Liu, Angela M.
    Wong, Kwong-Fai
    Jiang, Xiaoou
    Qiao, Yiting
    Luk, John M.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2012, 1826 (02): : 357 - 364